EGFR and neoplasm: Options include the same triplet regimen and bev, doublet chemotherapy and an anti-angiogenic agent, anti-EGFR (Epidermal Growth Factor Receptor)-based regimens only in the case of RAS wild-type tumours,1,2 or later lines options (regorafenib or trifluridine/tipiracil) in the case of clearly refractory disease.